Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01164007 | A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Apr 21, 2017 | clinicaltrials |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00976573 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 149 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00060333 | Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | completed | Phase 2 | 20 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 17, 2017 | clinicaltrials |
| NCT01781026 | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | completed | Phase 2 | 2 | Yale UniversityOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00003895 | Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00450372 | Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 38 | University of MiamiOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00109005 | Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT01189383 | IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 20 | Baylor Research InstituteOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT00256230 | Disulfiram in Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 7 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01251978 | Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) | completed | Phase 2 | 10 | New England Retina AssociatesOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT00135408 | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide | completed | Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 28, 2016 | clinicaltrials |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 155 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2016 | clinicaltrials |
| NCT01278940 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 31 | Oslo University HospitalOTHER | 0 | Aug 15, 2016 | clinicaltrials |
| NCT01216696 | Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1(CTLA4 NY-ESO-1) | completed | Phase 2 | 25 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Aug 12, 2016 | clinicaltrials |
| NCT01248936 | A Study of RO5185426 in Patients With Metastatic Melanoma | completed | Phase 2 | 374 | Hoffmann-La RocheINDUSTRY | 1 | Aug 12, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00948480 | Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells(DCVaccineMel) | completed | Phase 2 | 56 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00005610 | Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung | completed | Phase 2 | 28 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00098553 | Everolimus in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 53 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02809001 | The Effects of Autologous Fat Transfer on Preventing Expanded Skin From Expansion Failure | completed | Phase 1 / Phase 2 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02285413 | Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients | completed | Phase 2 | 54 | Radboud University Medical CenterOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00004104 | Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | completed | Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01455259 | Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Uppsala UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00588341 | Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT02662725 | Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases(IPI+RTS) | completed | Phase 2 | 73 | University Hospital, LilleOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01435369 | Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | completed | Phase 2 | 103 | Medivation, Inc.INDUSTRY | 2 | Jan 21, 2016 | clinicaltrials |
| NCT01983124 | Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib(BeyPro1) | completed | Phase 2 | 31 | Paola QueiroloOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00462982 | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00289016 | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | completed | Phase 2 | 50 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT02574260 | An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | completed | Phase 2 | 3 | BioVex LimitedINDUSTRY | 0 | Dec 17, 2015 | clinicaltrials |
| NCT00185302 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma | completed | Phase 2 | 28 | BayerINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT00257465 | Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | completed | Phase 1 / Phase 2 | 82 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00096382 | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 21, 2017source: clinicaltrials